Techno Medica Co., Ltd.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Techno Medica Co., Ltd.'s yearly results (2023–2026), compared with Healthcare companies in Japan. Tap ? on any ratio for what it means.
What stands out
- Self-Funding Ratio: Over the last 3 years its own operating cash covered its investment spending (capex) 18.4 times. Higher than almost all Healthcare companies in Japan.
- Tangible Net Worth Ratio: Of every ¥100 of net worth, ¥100 is tangible; the rest is goodwill and other intangibles, often from buying other companies. More tangible than 86% of Healthcare companies in Japan.
Cash quality
Profit Cash Ratio
¥94Over the last 3 years, every ¥100 of reported profit came with ¥94 of operating cash.
Lower than 76% of Healthcare companies in Japan.
Self-Funding Ratio
18.4×Over the last 3 years its own operating cash covered its investment spending (capex) 18.4 times.
Higher than almost all Healthcare companies in Japan.
Cash Locked Ratio
¥33For every ¥100 of sales, ¥33 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against ¥33 tied up three years earlier.
More money tied up than 69% of Healthcare companies in Japan.
Growth quality
Steadiness Ratio
2/3 · 2/3Sales grew in 2 of the last 3 years; profit grew in 2 of 3.
Less steady than 55% of Healthcare companies in Japan.
Growth Efficiency Ratio
−¥4Sales grew 20% in 3 years, but profit fell: ¥4 less profit per ¥100 of extra sales.
Lower than 78% of Healthcare companies in Japan.
Asset Productivity Ratio
+20% / -8%In 3 years sales changed by +20% while total assets changed by -8%. Sales grew faster than assets.
Balance-sheet strength
Debt Due Cover Ratio
—Data incomplete
Cash Cushion Ratio
—Data incomplete
Tangible Assets Ratio
100%Of every ¥100 the company owns, ¥100 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
More tangible than 84% of Healthcare companies in Japan.
Tangible Net Worth Ratio
100%Of every ¥100 of net worth, ¥100 is tangible; the rest is goodwill and other intangibles, often from buying other companies.
More tangible than 86% of Healthcare companies in Japan.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (12)
Techno Medica Co., Ltd. owes ¥0.16 for every ¥1 it owns. Net profit rose 7% in the year to Mar 2026, and shrank 2% a year on average over 3 years.
Compared with Healthcare companies in Japan · latest annual results Mar 2026.
P/E ratio
11.9Investors pay ¥11.9 for every ¥1 of Techno Medica Co., Ltd.'s yearly profit, lower than 72% of Healthcare companies in Japan.
P/B ratio
1.00The share price is 1.00 times Techno Medica Co., Ltd.'s book value per share, lower than 74% of Healthcare companies in Japan.
Market cap
¥13.7 BThe total market value of all of Techno Medica Co., Ltd.'s shares at today's price (share price × number of shares), smaller than 54% of Healthcare companies in Japan. PosiCap size class: Micro Cap.
Net worth (book value)
¥13.7 BWhat Techno Medica Co., Ltd. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
¥2,056Net worth divided by the number of shares. The share price of ¥2,057 is 1.0 times this, which is the P/B above.
Return on equity (ROE)
8.8%Techno Medica Co., Ltd. earned 8.8% on its shareholders' money over the last year, higher than 59% of Healthcare companies in Japan.
Owes vs Owns
0.16×Techno Medica Co., Ltd. owes ¥0.16 for every ¥1 it owns (low), lower than 84% of Healthcare companies in Japan.
Dividend yield
4.39%Techno Medica Co., Ltd. pays 4.39% of its share price as dividends a year, higher than 91% of dividend-paying Healthcare companies in Japan.
Revenue growth
+13%Revenue rose 13% in the year to Mar 2026, and grew 6% a year on average over 3 years.
Profit growth
+7%Net profit rose 7% in the year to Mar 2026, and shrank 2% a year on average over 3 years.
Profit margin
9.5%Techno Medica Co., Ltd. keeps ¥10 of every ¥100 of revenue as net profit.
Cash quality
1.03×Cash from Techno Medica Co., Ltd.'s business was 1.03× its reported profit in the year to Mar 2026 — its profit turned into cash.
Questions
What is Techno Medica Co., Ltd.'s P/E ratio?
Investors pay ¥11.9 for every ¥1 of Techno Medica Co., Ltd.'s yearly profit, lower than 72% of Healthcare companies in Japan.
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Techno Medica Co., Ltd.: ¥13.7 B ÷ ¥13.7 B (30 Jun 2026) = 1.0.
What is Techno Medica Co., Ltd.'s return on equity?
Techno Medica Co., Ltd. earned 8.8% on its shareholders' money over the last year, higher than 59% of Healthcare companies in Japan.
How much does Techno Medica Co., Ltd. owe compared with what it owns?
Techno Medica Co., Ltd. owes ¥0.16 for every ¥1 it owns (low), lower than 84% of Healthcare companies in Japan.
Does Techno Medica Co., Ltd. pay a dividend?
Yes. Techno Medica Co., Ltd. pays 4.39% of its share price as dividends a year, higher than 91% of dividend-paying Healthcare companies in Japan.
Is Techno Medica Co., Ltd.'s revenue growing?
Revenue rose 13% in the year to Mar 2026, and grew 6% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.